Table 1 Clinical characteristics of patients enrolled in the validation cohort
|  |  | Tissue Array 1 (n = 90) | Tissue Array 2 (n = 100) | Tissue Array 3 (n = 30) |
|---|---|---|---|---|
Cancer Type (%) | COAD | 0 (0.0) | 100 (100.0) | 30 (100.0) |
READ | 90 (100.0) | 0 (0.0) | 0 (0.0) | |
Sex (%) | Female | 42 (46.7) | 41 (41.4) | 13 (43.3) |
Male | 48 (53.3) | 58 (58.6) | 17 (56.7) | |
Age (Mean (SD)) | Â | 65.86 (11.64) | 67.51 (10.74) | 56.28 (17.50) |
Location (%) | Left | 90 (100.0) | 42 (42.0) | 10 (33.3) |
Right | 0 (0.0) | 50 (50.0) | 16 (53.3) | |
Unknown | 0 (0.0) | 8 (8.0) | 4 (13.3) | |
Survival (%) | OS | 90 (100.0) | 100 (100.0) | 0 (0.0) |
Unknown | 0 (0.0) | 0 (0.0) | 30 (100.0) | |
Tumor Size (%) |  >  = 5 | 45 (50.0) | 63 (63.6) | 21 (70.0) |
 < 5 | 45 (50.0) | 36 (36.4) | 8 (26.7) | |
Unknown | 0 (0.0) | 0 (0.0) | 1 (3.3) | |
T Stage (%) | T1 | 2 (2.2) | 0 (0.0) | 0 (0.0) |
T2 | 10 (11.2) | 4 (4.0) | 0 (0.0) | |
T3 | 76 (85.4) | 64 (64.0) | 0 (0.0) | |
T4 | 1 (1.1) | 32 (32.0) | 0 (0.0) | |
Unknown | 0 (0.0) | 0 (0.0) | 30 (100.0) | |
N Stage (%) | N0 | 54 (60.0) | 52 (52.0) | 28 (93.3) |
N1 | 24 (26.7) | 36 (36.0) | 0 (0.0) | |
N2 | 12 (13.3) | 12 (12.0) | 0 (0.0) | |
Unknown | 0 (0.0) | 0 (0.0) | 2 (6.7) | |
M Stage (%) | M0 | 89 (98.9) | 95 (95.0) | 30 (100.0) |
M1 | 1 (1.1) | 5 (5.0) | 0 (0.0) | |
AJCC7 Stage (%) | Stage I | 12 (13.3) | 4 (4.0) | 0 (0.0) |
Stage II | 41 (45.6) | 47 (47.0) | 0 (0.0) | |
Stage III | 36 (40.0) | 44 (44.0) | 0 (0.0) | |
Stage IV | 1 (1.1) | 5 (5.0) | 0 (0.0) | |
Unknow | 0 (0.0) | 0 (0.0) | 30 (100.0) | |
Tumor Grade (%) | I | 3 (3.3) | 0 (0.0) | 2 (6.7) |
I-II | 13 (14.4) | 14 (14.0) | 4 (13.3) | |
I-III | 0 (0.0) | 3 (3.0) | 0 (0.0) | |
II | 62 (68.9) | 56 (56.0) | 11 (36.7) | |
II-III | 6 (6.7) | 18 (18.0) | 4 (13.3) | |
III | 6 (6.7) | 9 (9.0) | 9 (30.0) | |
In vitro Validation | IHC | Yes | No | Yes |
Multiplex IHC | M Panel | M & F Panels | M & F Panels |